Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Metastatic Breast Cancer

CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Home
/
update
/
details

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

NextEdge Admin

29 Jan 2025

2 min 38 sec

Datar Cancer Genetics (DCG) has introduced an AI-powered video-reporting service for in-vitro chemosensitivity testing, offering real-time visual evidence of chemotherapy drugs’ effects on a patient’s tumor cells. This innovation enhances precision oncology by providing oncologists with concrete insights to guide personalized treatment selection, reducing trial-and-error approaches and minimizing toxicity risks.

The test evaluates the responsiveness of tumor cells to chemotherapy using high-resolution, time-lapse videos, allowing direct observation of drug efficacy. Designed for patients with solid organ tumors, DCG’s high-throughput platform assesses both standard-of-care (SoC) and off-label drugs, crucial for managing drug-resistant cancers.

DCG’s system integrates human-supervised AI to analyze real-time cellular responses, delivering quantifiable data on tumor cell elimination rates. "For the first time, we can see how a patient’s cancer cells react to treatments before administration," said Dr. Darshana Patil, Senior Director-Global Strategy and Medical Affairs.

Chemotherapy remains a primary cancer treatment, yet treatment failures often arise from empirical drug selection, especially in the absence of molecular biomarkers. DCG’s solution addresses this challenge by providing oncologists with verified, evidence-based treatment insights.

Key Features:

Real-time visualization of chemotherapy effects on tumor cells.
AI-driven quantification of tumor cell elimination.
Evaluation of both SoC and off-label drug options.
Faster treatment selection with reduced exposure to ineffective therapies.
Transparent, patient-friendly video reports for better treatment understanding.

Validated through extensive trials, the platform is now used in major oncology centers, improving treatment success and patient satisfaction. "This evidence-based approach is revolutionizing cancer care by optimizing treatment decisions and enhancing transparency," said Dr. Vineet Datta, Senior Director-Global Strategy and Business Development.